A Monocentric, Randomized, Double-blind Study to Assess the Feasibility of Conducting a Full-scale Randomized Controlled Trial (RCT) Assessing the Effect of Carbidopa/levodopa Ratio on Orthostatic Hypotension (OH) in Multiple System Atrophy - Parkinsonian Type (MSA-P) and Parkinson Disease (PD) Patients (CARBIDOH)

This study is aimed at patients with multi-system atrophy - parkinsonian type (P-MSA) or Parkinson's disease (PD) receiving dopaminergic drugs and suffering from orthostatic hypotension (OH).
OH is a drop in blood pressure when standing, which can lead to symptoms of dizziness, lightheadedness, a black veil in front of the eyes and, when severe, can lead to fainting. HO is one of the symptoms present in AMS-P and PD.
The standard treatment for parkinsonian symptoms of slowness and stiffness is the administration of antiparkinsonian drugs containing dopamine. These dopaminergic drugs always contain 1) levodopa (which is the precursor of dopamine) and 2) an enzyme inhibitor, which may be either benserazide (in the case of Madopar® and its generics) or carbidopa (in the case of Sinemet® or Stalevo® and their generics) and whose role is to potentiate the effect of levodopa.
It has long been known that dopaminergic drugs aggravate HO. Through various mechanisms, this worsening of HO is linked as much to levodopa as to the enzyme inhibitor with which it is combined. However, investigators do not know the respective effects of these two molecules on HO.
In this study, investigators examine how the ratio of Carbidopa to levodopa affects HO in the various assays of the dopaminergic drug under study.

开始日期2025-05-01

申办/合作机构

Centre Hospitalier Universitaire Vaudois

NCT06765668

/ Not yet recruiting临床4期

Open-Label Phase 4 Study of CREXONT® (Carbidopa and Levodopa) Extended Release Capsules in Parkinson's Disease Patients

The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).

开始日期2025-01-01

申办/合作机构

Impax Laboratories LLC

CTR20244711

/ Active, not recruitingN/A

卡左双多巴缓释片（ 50 mg/200 mg ）在健康参与者中的单剂量、随机、开放、两序列、四周期、完全重复交叉空腹／餐后状态下的生物等效性研究

主要研究目的：评价重庆赛维药业有限公司生产的卡左双多巴缓释片与MSD Sharp & Dohme GmbH持证的卡左双多巴缓释片（商品名：Sinemet®（息宁®））空腹和餐后单次口服给药在中国健康人群中的生物等效性。次要研究目的：评价受试制剂和参比制剂在中国健康成年参与者中的安全性。评价中国健康研究参与者单次空腹/餐后口服受试制剂和参比制剂后的安全性。

开始日期2024-12-25

申办/合作机构

重庆赛维药业有限公司

100 项与卡比多巴/左旋多巴相关的临床结果

登录后查看更多信息

100 项与卡比多巴/左旋多巴相关的转化医学

登录后查看更多信息

100 项与卡比多巴/左旋多巴相关的专利（医药）

登录后查看更多信息

748

项与卡比多巴/左旋多巴相关的文献（医药）

2025-03-01·PARKINSONISM & RELATED DISORDERS

Long-term, continuous, subcutaneous levodopa/carbidopa infusion with ND0612 in Parkinson's disease: 3-year outcomes from the open-label BeyoND study

Article

作者: Rudzińska, Monika ; Vasquez, Alberto ; Lopes, Nelson ; Kumar, Rajeev ; Roullet-Solignac, Isabelle ; Case, Ryan ; Muhlack, Siegfried ; Stocchi, Fabrizio ; Isaacson, Stuart ; Aldred, Jason ; Simuni, Tanya ; Taylor, Danette ; Greenberg, Jeffrey ; Azulay, Jean-Philippe ; Antonini, Angelo ; Yardeni, Tami ; Struck, Lynn ; Aralu, Cletus ; Rejdak, Konrad ; Djaldetti, Ruth ; Thomas, Karen ; Poewe, Werner ; Rizova, Yuliya ; Schwarz, Johannes ; Bonuccelli, Ubaldo ; Truong, Daniel ; Pazdera, Ladislav ; Savitt, Joseph ; Flitman, Stephen ; Patel, Neepa ; Gasparoli, Elisabetta ; Klos, Kevin ; Leehey, Maureen ; Ellenbogen, Aaron L. ; Gil, Ramon ; Hauser, Robert A. ; Cutler, Barry ; Durif, Franck ; Hassin-Baer, Sharon ; Espay, Alberto J. ; Bhatia, Perminder ; Defebvre, Luc ; Arkadir, David ; LeWitt, Peter ; Ebersbach, Georg ; Gurevich, Tanya ; Isa, Arnaldo ; Krawczyk, Malgorzata ; Sasson, Nissim ; Milo, Ron ; Kassubek, Jan-Rainer ; Biton, Victor ; Safirstein, Beth ; Ginsberg, Paul ; Klepitskaya, Olga ; Onofrj, Marco ; Yahalom, Gilad ; Danaila, Teodor

INTRODUCTION:

ND0612 is being investigated as a continuous, subcutaneous levodopa/carbidopa infusion, in combination with oral levodopa/carbidopa, for motor fluctuations in Parkinson's disease (PD). One-year data from the ongoing BeyoND study (NCT02726386) showed that the ND0612 regimen was safe and well tolerated and provided a sustained ≥2-h improvement in daily Good ON-time through 12 months of treatment.

METHODS:

We describe 3-year safety and efficacy outcomes for participants who completed 12 months of ND0612 treatment in the core study period and entered the extension phase.

RESULTS:

Of the 214 enrolled participants, 120 completed the core 1-year period, and 114 participants continued into the extension phase. Of these, 95/114 (83.3 %) completed 2 years and 77/114 (67.5 %) completed 3 years of study treatment. Key reasons for discontinuation were treatment-emergent adverse events (TEAEs) (n = 5 and n = 11 after 2 and 3 years, respectively) and withdrawal of consent (n = 9 and n = 5, respectively). TEAEs were reported by 105/114 (92.1 %) participants in Year 1, 77/114 (67.5 %) in Year 2, and 73/95 (76.8 %) in Year 3. While most participants experienced infusion site reactions, these led to discontinuation in only five participants during this extension. At Month 36, the mean reduction in OFF-time from baseline was 2.81 h and the increase in Good ON-time was 2.79 h.

CONCLUSIONS:

Three-year results from this open-label study support the long-term safety, tolerability, and efficacy of ND0612. For participants who entered the extension phase, the high rate of retention supports a favorable benefit-risk ratio of the ND0612 regimen for patients with PD experiencing motor fluctuations.

2025-02-01·EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

A novel levodopa-carbidopa three-layer gastroretentive tablet for improving levodopa pharmacokinetics

Article

作者: Zhou, Wenhu ; Yan, Peng ; Ding, Jinsong ; Zhao, Xiangcheng ; Zhang, Hailong

The narrow absorption window of levodopa and the significant impact of peripheral decarboxylase are the most limiting factors in maintaining prolonged and smooth plasma concentration in patients with Parkinson's disease (PD). Therefore, this study aims to design a novel gastroretentive carbidopa-levodopa three-layer tablet, which consists of an expansion layer, an immediate-release layer, and a sustained-release layer. The expansion layer rapidly expanded with sufficient structural strength and stayed in the beagle's stomach for more than 10 h, delineating excellent gastric retention effects. The immediate-release layer quickly released the drug and the sustained-release layer maintained a stable drug concentration. Importantly, pharmacokinetic data obtained under fed conditions demonstrated that the duration of efficacy of the three-layer tablets was significantly superior to that of the commercially available product Sinemet® CR, with effective levodopa blood levels remaining for up to 12 h. This is expected to offer more convenient clinical medication options for patients with PD.

2025-02-01·EUROPEAN JOURNAL OF NEUROLOGY

Cognitive Outcomes of Advanced Therapies in Parkinson's Disease: A Systematic Review of Apomorphine and Levodopa–Carbidopa Intestinal Gel Therapies

Review

作者: Papagno, Costanza ; Longo, Chiara

ABSTRACT:

Background:

Parkinson's disease (PD) treatments, such as apomorphine (APO) and levodopa–carbidopa intestinal gel (LCIG), represent advanced therapeutic options for managing motor symptoms. However, clear selection criteria and well‐defined cognitive outcomes are lacking. This systematic review specifically aimed to address these gaps by assessing the cognitive impact of APO and LCIG in PD patients.

Methods:

A systematic review was conducted following PRISMA guidelines, with searches in PubMed, Web of Science, Scopus, and Embase. Two authors screened studies based on key inclusion criteria, including at least two cognitive tests, and a follow‐up of 6 months or more. The risk of bias was evaluated using the Newcastle–Ottawa Scale (NOS).

Results:

Fifteen studies were identified (7 APO and 8 LCIG). APO generally preserved cognitive function over a 12‐month follow‐up, with some decreases in visuospatial memory and executive functions. LCIG, with a 28‐month follow‐up, showed more extensive cognitive decline, particularly in patients with pre‐existing impairments. Variability in cognitive tests made direct comparisons difficult.

Discussion:

APO may have a more favorable cognitive profile than LCIG. However, differences in follow‐up duration, moderate risk of bias, and inconsistent cognitive assessments warrant cautious interpretation. Improved patient selection and comprehensive cognitive evaluations are recommended for future practice.

213

项与卡比多巴/左旋多巴相关的新闻（医药）

2025-03-10

·米内网

【瞩目】华海大爆发，3大重磅新品同日获批

精彩内容日前，国家药监局官网显示，浙江华海药业的卡左双多巴缓释片、注射用阿糖胞苷、阿戈美拉汀片均以仿制4类报产获批，视同过评。其中，卡左双多巴缓释片为国产第2家；阿戈美拉汀片在2023年中国公立医疗机构终端销售规模超过9亿元，是抗抑郁化药TOP2产品。2025年03月10日药品批准证明文件送达信息卡左双多巴缓释片用于治疗原发性帕金森氏病，脑炎后帕金森氏综合征，症状性帕金森氏综合征（一氧化碳或锰中毒）等。近年中国公立医疗机构终端卡左双多巴缓释片销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局卡左双多巴缓释片在近年中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端市场规模稳步攀升，2023年超过5000万元，2024年上半年同比增长17.54%。米内网数据显示，卡左双多巴缓释片有3家企业拥有生产批文，石家庄四药拿下首仿，浙江华海药业是国产第2家，重庆华邦制药、广州绿十字制药等5家企业报产在审。 2023年中国公立医疗机构终端抗抑郁化药TOP5产品来源：米内网中国公立医疗机构药品终端竞争格局阿戈美拉汀片主要用于治疗成人抑郁症，能同时改善焦虑、失眠等伴随症状。该产品在2023年中国公立医疗机构终端销售额超过9亿元，同比增长近20%，是抗抑郁化药TOP2产品。阿戈美拉汀片有四川科伦药业、山东京卫制药、浙江华海药业等14家企业拥有生产批文，重庆药友制药、湖南湘中制药、河南福森药业等15家企业报产在审。华海药业表示，公司的卡左双多巴缓释片、注射用阿糖胞苷、阿戈美拉汀片获批，进一步丰富产品线，有助于提升公司产品的市场竞争力。近期，华海药业新品捷报频传。3月5日，公司发布公告，其子公司自主研发的HB0034注射液用于治疗泛发性脓疱型银屑病急性发作的多中心、双盲、随机、安慰剂平行对照的关键性临床试验达到主要疗效终点和所有关键次要疗效终点。目前全球范围内，尚未有国内企业自研的靶向IL-36R抗体获批上市，HB0034作为国内首个自研创新抗IL-36R抗体，可通过抑制IL-36通路发挥抗炎的生物学效应。资料来源：国家药监局官网、米内网数据库等注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 ●温馨提示● 因为微信公众号修改了推送规则，最近很多读者反映没有及时看到推文。把米内网设为“星标”，就能每天与我们不见不散啦，具体操作如下：【分享、点赞、在看】点一点不失联哦

上市批准申请上市一致性评价

2025-02-15

·药智网

百亿精分药赛道「再起风云」

在中枢神经系统领域（CNS），精神分裂症药物的发展和应用是一个重要方面。2024年，CNS领域大爆发，精神分裂症迎来破冰，数十年来首个用于治疗成人精神分裂症的新药Cobenfy获批上市。 2025年，CNS赛道持续火热：先是LB Pharmaceuticals宣布其潜在“first-in-class”苯甲酰胺类抗精神分裂症药物2期试验达到终点，即将迈入3期阶段，随后强生又以146亿美元收购Intra-Cellular，获得其重磅抗精神分裂症药物Caplyta。这些新动态无疑将为精神分裂症药物市场注入新的活力，进一步推动市场的发展变革。 1 前景广阔，短板待补据世界卫生组织2022年发布的数据，全球约2400万人患精神分裂症，流行率为0.33%，成年人群中为0.45%。2023年全球精神分裂症药物市场规模达到81.8亿美元。全球精神分裂症药物市场复合年增长率为5.26%，到2032年市场规模将达到129.7亿美元。这一规模的形成，是长期以来精神分裂症患者群体对药物需求的集中体现。众多制药企业针对这一病症研发并投入市场的各类药物，共同构成了这一庞大的市场体量。图1 三代抗精神分裂症药物图片来源：开源证券研报抗精神分裂症药物分三代，第一代抗精神分裂症药主要是以氯丙嗪、奋乃静、氟奋乃静、三氟拉嗪、舒必利为代表的脑内多巴胺D2受体阻断药，由于这一类药会非选择性地阻断多巴胺受体，常常引发严重副反应。第二代抗精神分裂症药是以氯氮平、奥氮平、利培酮、齐拉西酮为代表的D2/D3/D4受体拮抗剂和5-HT 2A受体拮抗剂，第二代药物相较于第一代药物减少了副作用，但仍会引发代谢综合征，高泌乳素血症等症状。第三代抗精神分裂症药物是以卢美哌隆、阿立哌唑、依匹哌唑以及卡利拉嗪为代表的D2/D3受体部分激动剂、5-HT 2A受体激动剂或拮抗剂和5-HT 1A受体部分激动剂，第三代抗精神病药对精神分裂症的治疗靶点扩展到D2受体阻断之外，以探索D2受体部分激动剂和新靶点如D3、5-HT1A、5-HT7和mGlu2/3受体的抗精神病作用。从全球精神分裂症患者数量及药物市场规模的增长态势，到三代抗精神分裂症药物的特性与局限，不难看出，尽管精神分裂症药物市场前景广阔，但在满足患者需求上仍有提升空间。 2 精分新药，蓄势待发据不完全统计，全球有超过300款精神分裂症创新药在研，其中创新药318款，改良型新药54款。除已经获批上市的Cobenfy外，还有10款新药处于临床3期获注册申请阶段（下表1），有望在2025年获批上市。表1 全球进入注册申请和临床3期阶段的抗精神分裂药物（部分）数据来源：药智数据其中，Brilaroxazine是一种Reviva Pharmaceuticals研发的新化学实体，对关键的血清素和多巴胺受体具有高亲和力和选择性，这些受体与包括精神分裂症、银屑病和间质性肺病在内的多种疾病的病理生理密切相关。2024年12月16日，Reviva Pharmaceuticals公布了Brilaroxazine的3期临床试验数据，结果显示精神分裂症小分子疗法Brilaroxazine3期临床结果积极。 Evenamide是一种口服的新化学实体，具有独特的作用机制，能够使异常钠通道活性诱导的谷氨酸释放正常化，特异性靶向电压门控钠离子通道，用于治疗精神分裂症。2024年4月30日，Newron Pharmaceuticals宣布Evenamide的潜在关键性临床试验008A取得了积极的顶线结果，达到2/3期临床主要终点，Newron指出，evenamide有望成为自氯氮平在1989年获批以来，首款针对治疗抵抗性精神分裂症的新疗法。 Olanzapine作为第二代的新型抗精神病药，作用于脑内D2受体和大脑皮质前额叶、边缘叶5-HT2A和D3受体，用于治疗精神分裂症。Olanzapine long acting injectable采用Medincell专有的共聚合物（copolymer）技术SteadyTeq，只需每月一针，能够稳定、持续地释放奥氮平。2024年5月8日，梯瓦和Medincell宣布其Olanzapine long acting injectabl在治疗精神分裂症成年患者的3期临床试验SOLARIS中达到主要终点，后续有望成功上市。 3 百舸争流，谁主沉浮？ CNS市场规模巨大，吸引各大MCN持续加码。强生长期致力于CNS领域。在产品层面，旗下艾司氯胺酮鼻喷雾剂自2019年获批联合口服抗抑郁药治疗难治性抑郁症后，又于2020年获批新适应症，市场增长迅猛，2023年销售额同比大增84.22%至6.89亿美元，预计2027年销售峰值可观。 1月13日，强生以146亿美元收购Intra-Cellular Therapies公司，获得其重磅抗精神分裂症药物Caplyta，该药分别在2019年、2021年获批用于成人精神分裂症与双相抑郁，且已提交辅助治疗重度抑郁症补充新药申请，若获批意义重大，强生预计其峰值年销售额可达50亿美元。此外，在研药物方面，KOR抑制剂Aticaprant处于Ⅲ期临床，有望达10亿-50亿美元销售额峰值；Caplyta的氘化形式ITI-1284处于Ⅱ期临床，针对广泛性焦虑症、阿尔茨海默病等。另有Lenrispodun（ITI-214）等多款药物处于不同临床阶段。艾伯维在CNS领域布局则更加深入。在精神分裂症领域，Vraylar表现出色，2024年全年销售额达32.67亿美元，同比增长18.4%；在偏头痛方面，Botox、Ubrelvy、Qulipta各展身手，Ubrelvy 2024年销售额10.06亿美元，同比增长23.4%，Qulipta全年销售额6.58亿美元，同比增长61.3%；帕金森病领域，Vyalev于2024年10月17日获美国FDA批准，成为首款基于左旋多巴的皮下24小时持续输注疗法，且还有处于Ⅲ期临床的D1/D5选择性激动剂Tavapadon。此外，艾伯维在CNS领域进行了多项BD交易，通过14亿美元收购Aliada Therapeutics，获处于1期临床的抗焦谷氨酸化β淀粉样蛋白（3pE-Aβ）抗体ALIA-1758，用于阿尔茨海默病研究；2024年5月与Gilgamesh Pharmaceuticals达成20亿美元合作，致力于开发针对情绪障碍和焦虑症等精神疾病的新一代疗法；从Cerevel Therapeutics获得的Emraclidine，作为潜在“best-in-class”的下一代抗精神病药物，针对精神分裂症和阿尔茨海默病进行Ⅱ期临床试验。 BMS也在CNS领域进行了重大投入，2023年12月豪掷140亿美元收购Karuna，从而收获数十年来精神分裂症领域的“First in Class”新药Cobenfy。2021年6月靶向tau蛋白的抗体候选药物PRX005在美国获得独家许可，并于2024年初开启2期临床试验；2024年5月，BMS与Prothena合作项目PRX019获全球许可，FDA已于2023年12月批准其IND申请，Prothena计划2024年底前启动1期临床试验。 4 结语 2025年，精神分裂症药物研发领域机遇与挑战并存。Cobenfy已率先破冰，众多潜力新药蓄势待发。参考资料 1.开源证券研报 2.艾伯维官网、强生官网、BMS官网、药智网等各种公开资料声明：本内容仅用作医药行业信息传播，为作者独立观点，不代表药智网立场。如需转载，请务必注明文章作者和来源。对本文有异议或投诉，请联系maxuelian@yaozh.com。责任编辑 | 史蒂文合作、投稿、转载开白 | 马老师 18323856316（同微信）阅读原文，是受欢迎的文章哦

临床3期临床2期上市批准引进/卖出并购

2025-02-10

·Pharmaceutical Technology

FDA approves AbbVie’s Emblaveo for intra-abdominal infections

The therapy will be used in conjunction with metronidazole for adults with complicated intra-abdominal infections. Credit: Studio Romantic/Shutterstock. AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in conjunction with metronidazole for people aged 18 and over with complicated intra-abdominal infections (cIAI) and limited treatment options. The approval marks the therapy as the first and only intravenous fixed-dose monobactam/β-lactamase inhibitor combo antibiotic. Emblaveo targets cIAI caused by Gram-negative microorganisms, including Escherichia coli and Klebsiella pneumoniae. The therapy combines the monobactam antibiotic, aztreonam, and the β-lactamase inhibitor, avibactam, which protects against serine β-lactamase hydrolysis and restores activity against bacteria producing Metallo-β-lactamases (MBLs). Previous outcomes related to aztreonam’s safety and efficacy for cIAI treatment support the therapy’s approval. The approval was also backed by the clinical trial outcomes from the Phase III trial, REVISIT, which assessed the therapy’s tolerability, efficacy and safety against serious Gram-negative bacterial infections, including those resistant to multiple drugs. AbbVie research and development executive vice-president and chief scientific officer Roopal Thakkar stated: “As bacteria evolve, industry, government and clinical experts must work together to ensure that the infectious disease community has the tools to advance public health. “We’re proud to offer this important novel treatment option to urgently address the significant threat of antimicrobial resistance.” The US regulator granted fast track status and qualified infectious disease product (QIDP) designation to the therapy in 2019. Its commercial availability in the country is expected in the third quarter of this year. Development of the therapy was a collaborative effort between AbbVie and Pfizer, with the former holding commercialisation rights in Canada and the US, and the latter handling other regions. It also benefited from public-private collaborations, including support from the US Department of Health and Human Services, the Administration for Strategic Preparedness and Response, the Biomedical Advanced Research and Development Authority (BARDA) and the EU’s Innovative Medicines Initiative (IMI) under the COMBACTE-CARE project. This consortium is backed by the COMBACTE pan-European clinical and laboratory networks. In October 2024, the FDA approved AbbVie’s Vyalev for treating motor fluctuations in the adult population with advanced Parkinson’s disease .

上市批准临床3期快速通道合格传染病产品临床结果

100 项与卡比多巴/左旋多巴相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	卡比多巴/左旋多巴	N04BA02	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
帕金森障碍	日本	Tatsumi Kagaku Co., Ltd.	1993-05-14
帕金森病	美国	Organon & Co.	1975-05-02
脑炎后帕金森病	美国	Organon & Co.	1975-05-02
继发性帕金森病	美国	Organon & Co.	1975-05-02

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
运动失调	临床3期	美国	AbbVie, Inc.	2017-02-09
运动失调	临床3期	芬兰	AbbVie, Inc.	2017-02-09
运动失调	临床3期	希腊	AbbVie, Inc.	2017-02-09
运动失调	临床3期	匈牙利	AbbVie, Inc.	2017-02-09
运动失调	临床3期	意大利	AbbVie, Inc.	2017-02-09
运动失调	临床3期	斯洛伐克	AbbVie, Inc.	2017-02-09
运动失调	临床3期	西班牙	AbbVie, Inc.	2017-02-09
安定药恶性综合征	临床3期	美国	AbbVie, Inc.	2015-10-26
安定药恶性综合征	临床3期	澳大利亚	AbbVie, Inc.	2015-10-26
安定药恶性综合征	临床3期	加拿大	AbbVie, Inc.	2015-10-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04380142 (FDA_CDER) 人工标引	临床3期	帕金森病	141	Oral IR carbidopa-levodopa	範壓構廠簾膚糧憲遞選(顧鹽餘夢淵淵鹽衊襯鬱) = 遞網顧範製醖醖鹽淵餘廠鏇憲齋壓積廠襯遞鏇 (觸獵窪憲觸醖願襯製醖, 0.50) 更多	积极	2024-10-16
NCT04380142 (FDA_CDER) 人工标引	临床3期	帕金森病	141	VYALEV	範壓構廠簾膚糧憲遞選(顧鹽餘夢淵淵鹽衊襯鬱) = 選遞糧壓觸遞鏇艱獵構廠鏇憲齋壓積廠襯遞鏇 (觸獵窪憲觸醖願襯製醖, 0.52) 更多	积极	2024-10-16
NCT04006210 (BouNDless, PRNewswire) 人工标引	临床3期	帕金森病	-	ND0612	製觸糧鏇艱網鑰鹹廠壓(獵蓋襯築壓獵衊鏇襯窪) = 願簾鬱壓淵製繭獵壓餘繭繭艱網鑰醖窪築願鑰 (製醖襯顧憲壓襯鹽繭蓋 ) 更多	积极	2024-09-30
NCT03670953 (FDA_CDER) 人工标引	临床3期	帕金森病	630	CREXONT	蓋遞襯鹽鑰繭蓋襯糧鏇(艱糧蓋鬱憲衊夢餘壓襯) = 築膚壓膚壓鏇構願壓蓋艱範範齋窪範廠觸鹹淵 (簾願積廠壓築醖鑰壓製 ) 更多	积极	2024-08-07
NCT03670953 (FDA_CDER) 人工标引	临床3期	帕金森病	630	Immediate-release carbidopa-levodopa	蓋遞襯鹽鑰繭蓋襯糧鏇(艱糧蓋鬱憲衊夢餘壓襯) = 遞遞觸夢獵觸顧餘獵鏇艱範範齋窪範廠觸鹹淵 (簾願積廠壓築醖鑰壓製 ) 更多	积极	2024-08-07
NCT04006210 (Phase 3 study, EAN2024)	临床3期	帕金森病	-	Levodopa/carbidopa infusion (ND0612)	醖鏇築餘膚餘襯餘膚觸(壓齋繭蓋憲窪憲範構廠) = Occurrence of adverse events (AEs) and serious AEs were generally consistent across subgroups (age, gender, region, and BMI). Consistent with the data for the full safety population, the most common AEs with ND0612 treatment across all subgroups were infusion site reactions. Overall, no relevant differences between subgroups were observed for AEs of particular interest, including dyskinesia, hallucinations, or falls. 窪鏇鑰糧繭願遞構醖糧 (艱糧獵觸齋遞壓網製淵 )	积极	2024-06-28
EAN2024	N/A	注射部位反应	-	ND0612	積壓積糧遞構製衊選簾(獵構觸夢鹹簾衊蓋糧範) = Most (88.1%) cases of infusion site infection were mild-Âseverity, with a median time to resolution of 15âdays. Infusion site infection led to discontinuation in only 12 (2.9%) patients. 簾範築願選築艱憲製鹽 (網獵鏇積衊願顧蓋觸鬱 )	-	2024-06-28
NCT02577523 (Phase 2 study, EAN2024)	临床2期	帕金森病	19	24h ND0612 infusion	鹹積艱築遞鹽顧淵願餘(壓網淵窪襯範繭糧觸鑰) = 73.7% of patients self-reported an improvement (including 36.8% very much/much improved) in their global impression of health on Day 3 壓積鹽積蓋願選製襯構 (製衊襯廠糧餘選夢餘憲 )	积极	2024-06-28
AAN2024	N/A	帕金森病	-	24-hour ND0612 infusion	製憲襯鹽積選餘醖壓憲(製網網鹹膚遞廠繭鹹製) = 鹽鬱願製膚範夢淵構顧築蓋壓鹹繭鏇醖繭艱蓋 (網築願網鏇遞鬱鹹顧艱 ) 更多	-	2024-04-09
RISE-PD (AAN2024)	临床3期	帕金森病	630	Immediate-Release Carbidopa-Levodopa (IR CD-LD)	繭鹹膚鹹窪鑰選夢製構(壓製夢觸簾齋膚鏇鏇衊) = 範糧鹹網顧繭繭獵鹽顧顧鹹衊鬱憲艱餘衊獵糧 (醖鹹鏇鹹觸艱餘鹹膚鹹, 6.0) 更多	积极	2024-04-09
RISE-PD (AAN2024)	临床3期	帕金森病	630	Extended-Release Carbidopa-Levodopa (IPX203)	繭鹹膚鹹窪鑰選夢製構(壓製夢觸簾齋膚鏇鏇衊) = 願選觸觸鹽廠願顧夢糧顧鹹衊鬱憲艱餘衊獵糧 (醖鹹鏇鹹觸艱餘鹹膚鹹, 3.7) 更多	积极	2024-04-09
NCT04006210 (BouNDless, Literature \| Pubmed \| Lancet Neurol) 人工标引	临床3期	帕金森病	381	ND0612	醖鏇鬱艱網觸鬱壓壓願(顧襯窪繭醖選築衊網齋) = 艱衊夢膚願襯構網願餘醖構廠憲憲觸顧艱壓範 (遞淵衊遞襯構網餘鹹窪, –0.94 ~ –0.02) 达到更多	积极	2024-03-15
	临床3期	帕金森病	381	levodopa+carbidopa	醖鏇鬱艱網觸鬱壓壓願(顧襯窪繭醖選築衊網齋) = 衊範繭襯鏇膚製齋網獵醖構廠憲憲觸顧艱壓範 (遞淵衊遞襯構網餘鹹窪, –2.65 ~ –1.74) 达到更多	积极	2024-03-15